Sign In
Buy PFE
$27.05
+0.290 (+1.08%)
At Close: Aug 10, 2026
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.
08:15am, Saturday, 25'th Jul 2026
Pfizer is a large and well-respected pharmaceutical company. Pfizer has been facing headwinds, leaving investors worried about the dividend.
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer
05:00pm, Thursday, 23'rd Jul 2026
Pfizer's payout ratio looks far too high. However, the company's dividend has increased despite headwinds in recent years.
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
12:56pm, Thursday, 23'rd Jul 2026
Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.
Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared
08:13am, Thursday, 23'rd Jul 2026
Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and ste
Pfizer Inc. $PFE Shares Purchased by ABN Amro Investment Solutions
03:47am, Thursday, 23'rd Jul 2026
ABN Amro Investment Solutions lifted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 11.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange C
Pfizer's prostate cancer drug combination gets US FDA priority review
04:48pm, Wednesday, 22'nd Jul 2026
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
04:30pm, Wednesday, 22'nd Jul 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA
2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends
08:00am, Wednesday, 22'nd Jul 2026
Healthcare is quietly becoming the value hunter's playground of 2026. While the mega cap tech trade keeps sucking up oxygen, two of the largest healthcare names in the S&P 500 are trading at forward m
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
11:06am, Tuesday, 21'st Jul 2026
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
06:46pm, Monday, 20'th Jul 2026
In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
10:01am, Monday, 20'th Jul 2026
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dimensional Fund Advisors LP Raises Stake in Pfizer Inc. $PFE
04:47am, Monday, 20'th Jul 2026
Dimensional Fund Advisors LP boosted its stake in Pfizer Inc. (NYSE: PFE) by 0.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
03:15am, Monday, 20'th Jul 2026
Pfizer has an attractive weight loss pipeline. However, it will be hard to take the lead from other companies in this fast-growing area.
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now
07:15am, Sunday, 19'th Jul 2026
Pfizer is deeply out of favor today, with a historically high dividend yield of 6.9%. The company is dealing with headwinds, but they are pretty normal, and Pfizer is addressing them.
Aviance Capital Partners LLC Has $4.65 Million Stake in Pfizer Inc. $PFE
04:25am, Sunday, 19'th Jul 2026
Aviance Capital Partners LLC boosted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 21.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange
